Laurion Capital Management’s Immunic IMUX Stock Holding History

Laurion Capital Management’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.38M	Buy	610,326 +222,110	+57%	+$2.74M	0.24%	96
2026 Q1	$4.31M	Hold	388,216	–	–	0.19%	145
2025 Q4	$2.07M	Buy	388,216 +200,000	+106%	+$1.47M	0.08%	105
2025 Q3	$1.66M	Sell	188,216 -2,290	-1%	-$20.2K	0.03%	169
2025 Q2	$1.33M	Buy	190,506 +167,663	+734%	+$1.54M	0.02%	189
2025 Q1	$249K	Buy	+22,843	New	+$247K	0.01%	223
2014 Q4	–	Sell	-29	Closed	-$241K	–	377
2014 Q3	$241K	Sell	29 -8	-22%	-$75.5K	0.01%	248
2014 Q2	$406K	Buy	+37	New	+$260K	0.01%	240

Other funds holding IMUX

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Laurion Capital Management's IMUX Position: Q2 2026 in Review

Laurion Capital Management increased its Immunic (IMUX) stake by 57% in Q2 2026, buying an estimated $2.74M and bringing the position to 610,326 shares worth $9.38M. The position accounts for 0.24% of the portfolio, ranked #96.

Laurion Capital Management first reported a position in IMUX in Q2 2014 and has held it in 8 quarters since. 55 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

Laurion Capital Management held 610,326 shares of Immunic worth $9.38M as of Q2 2026.
Laurion Capital Management bought 222,110 Immunic shares in Q2 2026, an estimated $2.74M.
Immunic made up 0.24% of Laurion Capital Management's portfolio in Q2 2026, its #96 holding.
Laurion Capital Management first reported a position in Immunic in Q2 2014 and has held it in 8 quarters since.
55 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on Laurion Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.